Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today positive initial Phase 2 data with revusiran
(ALN-TTRsc), an investigational RNAi therapeutic targeting transthyretin
(TTR) for the treatment of TTR cardiac amyloidosis.
for Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients investment picks